APOLLOHOSPApollo Hospitals Enterprise Ltd.
Apollo Hospitals Enterprise Q2 FY27 Results: Consolidated Net Profit ₹660 Crore on Total Income of ₹7,660 Crore
- Earnings
- hospital and healthcare services
Reviewed byRachit TripathiBlacklitt Research
Apollo Hospitals Enterprise reported consolidated total income of ₹7,660 crore and net profit of ₹660 crore for the quarter ended 30 Sep 2026. Standalone total income was ₹3,014 crore and standalone net profit ₹476 crore.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹7,660 crore, up 22.7% YoY and 9.7% QoQ
- Net profit and EPS: ₹660 crore, up 33.5% YoY; reported PAT ₹630 crore; diluted EPS from continuing operations ₹43.71
- Finance costs: ₹114 crore, up 15.6% YoY from ₹99 crore
- Healthcare Services: revenue ₹3,900 crore, up 23% YoY; EBITDA ₹937 crore
Standalone
The company on its own, without its subsidiaries
- Total income: ₹3,014 crore, up 20.7% YoY and 11.5% QoQ
- Net profit and EPS: ₹476 crore, up 13.3% YoY; basic EPS ₹33.08 against ₹29.20 a year earlier
- Other income: ₹111 crore, down 21.0% YoY and up 136.5% QoQ
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 7,660 | 6,243 | +22.7% | 6,980 | +9.7% | |
| Revenue from operations | 7,615 | 6,189 | +23.0% | 6,932 | +9.9% |
| Other income | 45 | 55 | -17.8% | 48 | -6.5% |
| 660 | 494 | +33.5% | 610 | +8.0% | |
| Profit before tax | 903 | 681 | +32.6% | 808 | +11.8% |
| Finance costs | 114 | 99 | +15.6% | 108 | +5.5% |
| Depreciation | 230 | 205 | +12.1% | 222 | +3.5% |
| Net profit margin | 8.61% | 7.91% | +0.70 pp | 8.75% | -0.14 pp |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit rose faster than total income. Consolidated net profit was ₹660 crore, up 33.5% on ₹494 crore a year earlier, while total income rose 22.7%, from ₹6,243 crore to ₹7,660 crore. Profit before tax grew 32.6%, to ₹903 crore from ₹681 crore. Revenue from operations rose 23.0%, to ₹7,615 crore, and other income fell 17.8%, to ₹45 crore.
The press release attributes the revenue growth to a robust volume increase in specialties and high complexity clinical work, with oncology up 28%, gastro up 27%, cardiac and ortho up 20% and urology up 26%. International patient services revenue rose 37%.
Finance costs rose to ₹114 crore from ₹99 crore, up 15.6%, and depreciation to ₹230 crore from ₹205 crore, up 12.1%. The press release puts Apollo 24/7 costs at ₹91 crore in the quarter, including a non-cash ESOP charge of ₹14 crore, against ₹126 crore including ₹32 crore in Q2 FY26.
Apollo Specialty Hospitals and Apollo Fertility Centre are classified as discontinued operations, and their total income was ₹142.6 crore in the quarter. The notes also record a Labour Codes exceptional item of ₹19.2 crore on the consolidated statement, an increase in gratuity and leave liability for the year ended 31 Mar 2026 that the filing calls regulatory driven and non-recurring.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 3,014 | 2,497 | +20.7% | 2,703 | +11.5% | |
| Revenue from operations | 2,903 | 2,356 | +23.2% | 2,656 | +9.3% |
| Other income | 111 | 141 | -21.0% | 47 | +136.5% |
| 476 | 420 | +13.3% | 385 | +23.5% | |
| Profit before tax | 622 | 554 | +12.3% | 501 | +24.2% |
| Finance costs | 71 | 58 | +23.0% | 68 | +4.2% |
| Depreciation | 141 | 122 | +15.5% | 134 | +5.0% |
| Net profit margin | 15.78% | 16.81% | -1.03 pp | 14.25% | +1.53 pp |
| EPS, basic (₹) | 33.08 | 29.20 | +13.3% | 26.79 | +23.5% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 13.3% to ₹476 crore, slower than total income, which rose 20.7% to ₹3,014 crore. Revenue from operations rose 23.2%, to ₹2,903 crore from ₹2,356 crore, while other income fell 21.0%, to ₹111 crore from ₹141 crore.
Against the quarter before, standalone net profit rose 23.5%, faster than total income at 11.5%. Profit before tax was ₹622 crore against ₹501 crore, and basic EPS was ₹33.08 against ₹26.79.
Finance costs were ₹71 crore against ₹58 crore a year earlier, up 23.0%, and depreciation was ₹141 crore against ₹122 crore, up 15.5%. Standalone other income is 3.7% of total income this quarter and 17.9% of profit before tax.
Inference
In a filing on 04 Nov 2026, the company said Madhu Sasidhar, a designated senior managerial personnel, will cease to be President & CEO - Hospitals Division at the close of business on 14 Nov 2026, on completion of his employment tenure, and that there is no other material reason for the cessation. Ritu Garg, Anand Wasker and N. Venkatesan were designated senior management personnel with effect from 4 Nov 2026, and the support functions previously reporting to the President & CEO will report to a project management office under the guidance of the Managing Director.
Apollo Health and Lifestyle has transferred its stakes in Apollo Specialty Hospitals Private Limited and Apollo Fertility Centre Private Limited to Kids Clinic India Limited for cash consideration of about ₹765 crore and an effective stake of about 9.9% in Kids Clinic India. The letter gives closure as 3 Nov 2026, while Note 8 gives 12 Oct 2026. In Note 7, the Revenue Department of Karnataka cancelled a land grant order to a subsidiary, Imperial Hospitals & Research Centre, which has challenged it; the High Court granted an interim stay on 10 Apr 2026, and the group believes the matter would be settled in its favour. The auditors' conclusion is not modified for this matter.
The board approved a composite scheme on 30 Jun 2025 that would demerge the omni channel pharmacy distribution and digital health platform businesses into Apollo Healthtech Limited, and the company has filed a petition before the National Company Law Tribunal seeking sanction of the scheme. The company paid dividends of ₹143.8 crore in the six months to 30 Sep 2026, and consolidated net cash from operating activities was ₹1,493.3 crore in the same period. The filing does not give a date for the tribunal's decision, the gain or loss, if any, on the divestment, or a successor for Madhu Sasidhar's role.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
